PV Bulletin

Ixchiq (Chikungunya vaccine (live)) - Safety measures following PRAC review

PRAC recommends safety measures for Ixchiq due to risk of aseptic meningitis and serious side effects in elderly.

Primary source: European Medicines Agency (EMA)

PV Impact Brief

Urgency: HighConfidence: high

What changed

PRAC recommended safety measures for Ixchiq, including updated product information and guidance for elderly use, based on the risk of aseptic meningitis and serious side effects.

Why it matters

This affects the benefit-risk profile of Ixchiq, particularly in elderly patients, and may require updates to labeling and risk minimization activities.

Action needed

Update product information and guidance for use in elderly populations for Ixchiq; ensure compliance with PRAC recommendations.

Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal ManagementLabeling
Owner

Regulatory Intelligence Lead

Review cadence

Single event

Regulatory action details

Action type
PRAC recommendation
Publication date
2026-06-05
Safety issue
Implementation of safety measures following a PRAC review regarding the risk of aseptic meningitis and serious side effects in elderly populations (VR/0000347283).

Affected products

  • Ixchiq
    Valneva

PV internal implications

Updated product information and guidance for use in elderly populations.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 5, 2026

Full briefing

Practical implication

Update product information and guidance for use in elderly populations for Ixchiq; ensure compliance with PRAC recommendations.

EMA's PRAC concluded a review of Ixchiq (chikungunya vaccine) and recommended implementation of safety measures, including updates to product information and guidance for use in elderly populations, due to risks of aseptic meningitis and serious side effects.

What changed: PRAC recommended safety measures for Ixchiq, including updated product information and guidance for elderly use, based on the risk of aseptic meningitis and serious side effects.

Why it matters: This affects the benefit-risk profile of Ixchiq, particularly in elderly patients, and may require updates to labeling and risk minimization activities.

Practical implication: Update product information and guidance for use in elderly populations for Ixchiq; ensure compliance with PRAC recommendations.

View original source

Published from the Firecrawl agent regulatory extraction pipeline.

#Safety Signals#PRAC recommendation#European Medicines Agency (EMA)#other#firecrawl-agent#regulatory-extraction

Related updates for your role

publicFood and Drug Administration (FDA) · United States · Updated Jun 29, 2026

eMDR System Enhancements - Production Deployment

Urgency: High

Update electronic safety reporting systems and pharmacovigilance databases to implement new rules to ensure all submissions use GENC 3-letter country codes and include the required fields as of July 20, 2026.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward